| Title |
Letermovir: First Global Approval
|
|---|---|
| Published in |
Drugs, December 2017
|
| DOI | 10.1007/s40265-017-0860-8 |
| Pubmed ID | |
| Authors |
Esther S. Kim |
| Abstract |
Letermovir (Prevymis™) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 55 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 55 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 12 | 22% |
| Student > Ph. D. Student | 5 | 9% |
| Researcher | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 4 | 7% |
| Other | 8 | 15% |
| Unknown | 16 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 33% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 7% |
| Chemistry | 3 | 5% |
| Mathematics | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 16 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2018.
All research outputs
#14,833,894
of 23,015,156 outputs
Outputs from Drugs
#2,733
of 3,287 outputs
Outputs of similar age
#252,320
of 441,864 outputs
Outputs of similar age from Drugs
#23
of 27 outputs
Altmetric has tracked 23,015,156 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,287 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 441,864 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.